Literature DB >> 11818162

Varicella seroprevalence in a random sample of the Turkish population.

G Kanra1, S Tezcan, S Badur.   

Abstract

Chicken pox highly contagious and common throughout the world, is an infectious disease caused by varicella zoster virus (VZV). This study was conducted to determine the seroprevalence of VZV in a population under age 30 and to identify the relationship of VZV seroprevalence and several characteristics of the study subjects in nine provinces of Turkey. The sampling method of 30 clusters recommended for field studies was used for selecting subjects of a pre-determined number in the rural and urban areas in each province. For this, a total of 60 groups, 30 clusters in the rural and 30 in the urban areas were determined. It was planned that a total of 4800 subjects, including 600 subjects from five big provinces (Istanbul, Ankara, Izmir, Adana, Diyarbakir) and 450 subjects from the remaining smaller provinces (Samsun, Erzurum, Trabzon, Edirne), be included in the study. ELISA method was used to examine the blood samples for VZV seropositivity. Positive VZV seroprevalence was detected in 77.8% of 4387 subjects under age 30 in nine provinces of Turkey. There was no difference in seroprevalence rate between rural and urban areas. Seroprevalence was found to be 79.0% in urban areas and 76.3% in rural areas. Seroprevalence increased with age. Seroprevalence was 20% at the age of 1 year, subsequently increased to 40% at the age of 4 years, 60% at the age 6 years, 80% at the age of 8 years, 85% at the age of 10 years, and then remained at 85-90% in subjects over the age of 10 years. In order to develop vaccination protocols and take appropriate preventive health care measures against diseases in different countries, it is very important to know the seroprevalence of any disease for an individual country.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818162     DOI: 10.1016/s0264-410x(01)00459-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  The epidemiology and economic impact of varicella-related hospitalizations in Turkey from 2008 to 2010: a nationwide survey during the pre-vaccine era (VARICOMP study).

Authors:  Ener Cagri Dinleyici; Zafer Kurugol; Ozden Turel; Nevin Hatipoglu; Ilker Devrim; Hasan Agin; Ilker Gunay; Olcay Yasa; Muferet Erguven; Nuri Bayram; Ali Kizildemir; Emre Alhan; Emine Kocabas; Hasan Tezer; H Hakan Aykan; Nazan Dalgic; Betul Kilic; Gulnar Sensoy; Nursen Belet; Nihan Uygur Kulcu; Aysu Say; Mehmet Ali Tas; Ergin Ciftci; Erdal Ince; Halil Ozdemir; Melike Emiroglu; Dursun Odabas; Zeynel Abidin Yargic; Cagatay Nuhoglu; Kursat Bora Carman; Solmaz Celebi; Mustafa Hacimustafaoglu; Murat Elevli; Zahide Ekici; Umit Celik; Meda Kondolot; Mustafa Ozturk; Anil Tapisiz; Metehan Ozen; Harun Tepeli; Aslinur Parlakay; Ates Kara; Ayper Somer; Bahar Caliskan; Sevtap Velipasalioglu; Selim Oncel; Emin Sami Arisoy; Ekrem Guler; Tahir Dalkiran; Denizmen Aygun; Saadet Akarsu
Journal:  Eur J Pediatr       Date:  2011-12-16       Impact factor: 3.183

2.  Varicella vaccination in Europe: are we ready for a universal childhood programme?

Authors:  Nitu Sengupta; Robert Booy; H J Schmitt; Heikki Peltola; Pierre Van-Damme; R Fabian Schumacher; Magda Campins; Carlos Rodrigo; Terho Heikkinen; Jane Seward; Aisha Jumaan; Adam Finn; Per Olcén; Nancy Thiry; Catherine Weil-Olivier; Judith Breuer
Journal:  Eur J Pediatr       Date:  2007-03-03       Impact factor: 3.860

3.  Varicella immunity in Iran: an age-stratified systematic review and meta-analysis.

Authors:  Abbas Allami; Navid Mohammadi
Journal:  Iran J Microbiol       Date:  2014-12

4.  Sero-Prevalence of Antibodies against Varicella Zoster Virus in Children under Seven-Years Old in 2012 in Tehran, Iran.

Authors:  Yasaman Vojgani; Saeed Zarei; Samira Rajaei; Leili Chamani-Tabriz; Fatemeh Ghaemimanesh; Nematallah Mohammadinia; Mahmood Jeddi-Tehrani
Journal:  Iran J Public Health       Date:  2014-11       Impact factor: 1.429

Review 5.  Varicella infection in the Middle East: Prevalence, complications, and vaccination.

Authors:  Mariam Al-Turab; Wassim Chehadeh
Journal:  J Res Med Sci       Date:  2018-04-26       Impact factor: 1.852

6.  Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.

Authors:  Lara J Wolfson; Vincent J Daniels; Matthew Pillsbury; Zafer Kurugöl; Cuneyt Yardimci; Jeffrey Kyle; Ener Cagri Dinleyici
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

7.  Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial.

Authors:  Roman Prymula; Robert Simko; Michael Povey; Andrea Kulcsar
Journal:  BMC Pediatr       Date:  2016-01-13       Impact factor: 2.125

8.  The clinical and economic burden of varicella in the Middle East: a systematic literature review.

Authors:  Nawal Al Kaabi; Fatma Mohd Ali Sultan Al Olama; Mamoun Al Qaseer; Idris Al Ubaidani; Ener Cagri Dinleyici; Wail Ahmad Hayajneh; Abdul Rahman Bizri; Maysoon Loulou; Tidiane Ndao; Lara J Wolfson
Journal:  Hum Vaccin Immunother       Date:  2019-09-03       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.